key: cord-345628-a4c46m2w
authors: Unudurthi, Sathya D.; Luthra, Priya; Bose, Rajendran J.C.; McCarthy, Jason; Kontaridis, Maria Irene
title: Cardiac inflammation in COVID-19: Lessons from heart failure
date: 2020-09-21
journal: Life Sci
DOI: 10.1016/j.lfs.2020.118482
sha: 
doc_id: 345628
cord_uid: a4c46m2w

Cardiovascular disease (CVD) is the most common co-morbidity associated with COVID-19 and the fatality rate in COVID-19 patients with CVD is highest compared to other comorbidities, such as hypertension and diabetes. Preliminary data suggest that COVID-19 may also cause or worsen cardiac injury in infected patients through multiple mechanisms such as ‘cytokine storm’, endotheliosis, thrombosis, lymphocytopenia etc. Autopsies of COVID-19 patients reveal an infiltration of inflammatory mononuclear cells in the myocardium, confirming the role of the immune system in mediating cardiovascular damage in response to COVID-19 infection and also suggesting potential causal mechanisms for the development of new cardiac pathologies and/or exacerbation of underlying CVDs in infected patients. In this review, we discuss the potential underlying molecular mechanisms that drive COVID-19-mediated cardiac damage, as well as the short term and expected long-term cardiovascular ramifications of COVID-19 infection in patients.

peptide; hs-TnI, high sensitivity cardiac troponin I; CRP, C-reactive protein; TMPRSS2, transmembrane protease serine 2.

Corona Virus Disease-2019 is an ongoing pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which originated in Wuhan province in China (Zhu et al., 2020) . It is a highly contagious disease that has affected more than 187 countries across the globe, infecting over 27 million people and resulting in the death of over 880,000 people. In the US alone, we have had over 6.2 million people infected and around 188,000 deaths, and these counts continue to increase everyday(figures are current at the time of writing this manuscript)(Center for Systems Science and Engineering). To control its spread, strict quarantine measures have been adopted world-wide and there has been a strong push towards rapid development of diagnostics, therapeutics and vaccines.

Most patients infected with SARS-CoV-2 are asymptomatic, or develop mild to moderate symptoms, and recover in 1-2 weeks. The most common symptoms of COVID-19 include shortness of breath, low-grade hyperthermia and cough (Holshue et al., 2020) . However, subsets of patients develop pneumonia and severe dyspnea, and many of these patients end up in the intensive care unit and require intubation (Wu, Wu, Liu, & Yang, 2020) . Interestingly, it remains unclear why the degree of severity varies from patient to patient, and identification of the contributing factors that differentiate a moderate from a severe COVID-19 response remains an active and critical line of investigation. What we do know so far is that COVID-19 mainly attacks the respiratory system and that the hallmark features of severe COVID-19 infection include diffuse alveolar damage with Acute Respiratory Distress Syndrome (ARDS). Moreover, while the lung seems to be the most overtly affected organ in this disease, accumulating evidence suggests that SARS-CoV-2 also severely affects additional organs and tissues, including the heart, brain, large intestine, kidneys and spleen (Bradley et al., 2020; Wichmann et al., 2020) .

Initial reports suggested that systemic hyper-inflammation, which leads to Cytokine Release Syndrome (CRS, aka the 'cytokine storm'), is thought to be one of the main causal mechanism for the serious complications and high mortality associated with COVID-19. Inflammation is initially triggered in the lungs due to SARS-Cov-2 induced alveolar epithelial cell damage, evoking extensive immune cell infiltration (Li & Ma, 2020) . However, this local inflammatory response also induces the release of systemic pro-inflammatory cytokines, resulting in the hyper-inflammation of multiple organs, and leading to subsequent tissue damage and death of patients (Ye, Wang, & Mao, 2020) . While cytokine storm causes significant morbidity and mortality in COVID-19 patients, multiple pathophysiological mechanisms such as endotheliosis, dysregulation of Renin-Angiotensin-Aldosterone System (RAAS), thrombosis, lymphocytopenia, T-cell anergy might also contribute to the morbidity (Amraei & Rahimi, 2020) (Jesenak et al., 2020) Obstructive Pulmonary Disorder (COPD), diabetes, CVD and cerebrovascular diseases (Wang, Li, Lu, & Huang, 2020) . Even though hypertension is the most common comorbidity, the case fatality rate is highest in patients with underlying CVD (Worldometer).

Preliminary reports suggest a significant CVD burden in COVID-19 patients that require hospitalization. Clinical data from COVID-19 patients indicate elevated levels of cardiac injury biomarkers, such as N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitivity cardiac troponin I (hs-TnI) and C-reactive protein (CRP) (Madjid, Safavi-Naeini, Solomon, & Vardeny, 2020) . In addition, preliminary autopsy reports from patients that succumbed to severe COVID-19 infection show severe right ventricular dilation, cardiac necrosis and infiltration of immune cells into the myocardium (Fox et al., 2020; Tavazzi et al., 2020; Yao et al., 2020) . While the exact sequela and the relationship between these cardiac pathologies are still undetermined, it is becoming increasingly clear that inflammation, in addition to other factors plays an important role in promoting COVID19 related cardiac injury.

While inflammation plays an important role in pathogenesis of COVID -19, it is noteworthy that inflammation is also an important driver of cardiac pathological responses to stress, including following myocardial infarction (MI) and transition to heart failure (HF). In both ischemic and non-ischemic HF, immune cells infiltrate the myocardium and release pro-inflammatory cytokines which regulate maladaptive cardiac remodeling (Epelman, Liu, & Mann, 2015) . Recent studies in humans and animals have greatly advanced our understanding of the molecular mechanisms that drive these cardiac inflammatory responses, as well as the shortterm and long-term consequences of the immune cell infiltration to the heart. In this review, we will discuss SARS-CoV-2 pathogenesis, disease mechanisms that mediate cardiac injury in COVID-19 and highlight the common inflammatory mechanisms that mediate HF between COVID-19 and ischemic/non-ischemic heart disease.

SARS-CoV-2, which belongs to the Coronavirus family, is an enveloped positive single-stranded RNA virus, and is derived from a novel strain of Beta coronavirus . Historically, human coronavirus infections, from strains such as hCOV-OC43, HKU, and 229E, caused mild common cold like symptoms (Z. W. . However, since 2000, at least two highly pathogenic and deleterious coronavirus strains have emerged, including SARS-CoV in 2002-2003 and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012. SARS-CoV originated in China and rapidly spread to five of the seven continents, mainly through air travel; it resulted in 8,098 cases with death rate of 10%. MERS, on the other hand, originated in the Arabian Peninsula, and resulted in 2,494 confirmed cased, but with devastating fatality rate of 35% (Petrosillo, Viceconte, Ergonul, Ippolito, & Petersen, 2020) . Viral entry into host cells is a key determinant of infectivity and disease pathogenesis. While the virus entry is dictated by efficient binding of the virus to host receptor, severity of infectivity and disease pathogenesis are determined by the host immune system. Generation of viral specific neutralizing antibodies by the host can definitively dampen the viral load and infectivity J o u r n a l P r e -p r o o f Journal Pre-proof SARS-CoV-2 shares significant structural and genetic similarity with the original SARS-CoV. Both viruses are spherical in shape and have multiple transmembrane spike (S) glycoproteins embedded in the virion envelope that form homotrimers (Walls et al., 2020) . In both cases, infection in humans is mediated mainly by binding of the viral surface spike protein (S) to the human angiotensin-converting enzyme 2 (ACE2) receptor following its cleavage and activation by transmembrane protease serine 2 (TMPRSS2) or cathepsins secreted by the host. (Gallagher & Buchmeier, 2001; Hoffmann et al., 2020; Letko, Marzi, & Munster, 2020; Simmons, Zmora, Gierer, Heurich, & Pohlmann, 2013; Yan et al., 2020) . The S1 harboring receptor binding domain binds to the cellular receptor ACE2, while the transmembrane unit S2 facilitates fusion of the viral membrane with host cellular membrane. Membrane fusion is facilitated by cleavage of S protein by host cell proteases such as TMPPRSS2 or cathepsin at the S1/S2 and the S2′ site, which results in S protein activation (Hoffmann et al., 2020; Hulswit, de Haan, & Bosch, 2016; Millet & Whittaker, 2018) . This cleavage of the S protein in the constitutive endocytic pathway of infected cells or during viral entry into target cells is a key determinant of viral infectivity and pathogenesis (Lan et al., 2020; Shang et al., 2020; .

In addition, the SARS-CoV-2 spike protein also contains a polybasic cleavage site, allowing it to also be processed by furin-like proteases, a feature also shared by other highly pathogenic avian flu viruses (Klenk & Garten, 1994) (Steinhauer, 1999) . Recent reports demonstrate that furin cleaves the S protein precursor of SARS-Cov2 virus to generate a polybasic ArgArg-Ala-Arg (RRAR) C-terminal amino acid sequence on S1 protein, which increases the association of the virus to neuropilin-1 (NPR-1), a cell receptor widely expressed in respiratory and olfactory epithelium. In vitro and in vivo experiments suggest that this binding of SARS-Cov2 to NPR-1 receptor enhances the infectability of SARS-Cov2 in cell culture (Daly et al., 2020) and may be a significant contributing factor for enhanced tropism and infectability of SARS-Cov2 in humans, (Cantuti-Castelvetri et al., 2020) . Compared to previous corona viruses, this combination of high ACE2 receptor affinity and enhanced tropism due to the presence of a polybasic cleavage site in its spike protein enhances SARS-CoV-2's ability to infect multiple organs, including the heart. Furin itself is a ubiquitously expressed transmembrane protein and its function has been wellcharacterized in the heart (Ichiki et al., 2013; Thomas, 2002; . In the case of COVID-19, protein-proofed single-cell RNA (pscRNA) profiling studies examining the effects of infection on expression of ACE2, TMPRSS2 or furin in the heart, revealed that cardiomyocytes are a critical target for infection by SARS-CoV-2, preceded only by lung alveolar type II (AT2) cells and macrophages (L. Zhou et al., 2020) . Two additional studies demonstrated that SARS-CoV-2 can enter the cell membrane and replicate in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Microscopy and immunofluorescence studies confirmed that the virus localizes in the perinuclear region and induces apoptosis in the infected hiPSC-CMs, suggesting a deleterious outcome for cardiac tissue in response to COVID-19 (Sharma, Garcia, Arumugaswami, & Svendsen, 2020) (Bojkova et al., 2020) . Thus, entry receptor and proteases present good therapeutic targets to combat SARS-CoV-2 infection

J o u r n a l P r e -p r o o f Journal Pre-proof Damage to cardiac tissue has been previously reported in response to the coronavirus outbreaks. Approximately 8% of all SARS patients had CVD comorbidities and the presence of CVD or diabetes mellitus in SARS-infected patients led to at least 12-fold increased death rate (Booth et al., 2003; Chan et al., 2003) . CVD (30%) and hypertension (50%) comorbidities were also significantly associated with MERS (Badawi & Ryoo, 2016). Recent reports from Wuhan, Italy and US suggest that CVD is one of the most common comorbidities associated with COVID-19 (S. Shi et al., 2020) (Onder, Rezza, & Brusaferro, 2020 ) (Richardson et al., 2020) . In addition, COVID-19 patients with CVD have a higher mortality rate (around 10.5%) as compared to other comorbidities such as hypertension (6%), diabetes (7.3%), or chronic respiratory disease (6.3%) (J. Yang et al., 2020) . In a study of 416 hospitalized patients with confirmed COVID-19, approximately 20% had elevated hs-TnI levels, indicative of an increased pathological response in the heart. Patients with these elevated cardiac injury biomarkers also had significantly higher mortality rates (~50%), as compared to those without heart injury (~4.5%) (S. Shi et al., 2020) . Similar findings were reported in a separate independent study, where the mortality rate among patients with elevated Troponin T (TnT), another cardiac injury biomarker, was ~60%, whereas the mortality rate in patients with normal TnT levels was ~9% . Examination of additional cardiac injury biomarkers, including CRP and NT-proBNP, all consistently point towards a similar conclusion (Lippi, Lavie, & Sanchis-Gomar, 2020) .

While there was an increase in multiple cardiac injury biomarkers, the physiological and pathological manifestation of COVID-19 infection in heart spans a broad spectrum. In severe cases, direct acute myocardial injury characterized by concentric left ventricular hypertrophy with a dilated, severely hypokinetic right ventricle and cardiac amyloidosis has been reported (Fried et al., 2020) ..Cardiac rhythm disorders have also been observed in patients with COVID-19. Guo et al reported an overall ventricular tachycardia (VT)/ventricular fibrillation (VF) incidence rate of 7% during hospitalization However in a larger clinical trial involving 700 COVID-19 positive patients, only 1.3% of the patients had cardiac arrests, 3.6% had atrial fibrillation, 1.3% had significant bradyarrhythmia and 1.4% had nonsustained VT (Bhatla et al., 2020) . Vascular complications of COVID-19 have also been reported including stroke, cutaneous lesions on the toes, and Kawasaki disease like systemic vasculitis in young children with severe COVID-19 (E. W. Cheung et al., 2020; Landa, Mendieta-Eckert, Fonda-Pascual, & Aguirre, 2020) .Preliminary autopsy and endocardial biopsy reports suggest low grade myocardial inflammation as evidenced by T-lymphocytic infiltration (Sala et al., 2020) and CD68+ macrophage infiltration in heart. (Inciardi et al., 2020) (Doyen, Moceri, Ducreux, & Dellamonica, 2020; Tavazzi et al., 2020) . In addition, evidence of viral particles within vascular endothelial cells and diffuse vascular endothelial cell injury in lung, heart, and other organs have also been reported (Menter et al., 2020) (Varga et al., 2020) . Histological evidence of acute myocarditis in COVID-19 patients is limited and additional autopsy and endomyocardial biopsy studies are needed to differentiate the pattern and proportion of cardiac damage caused by acute myocarditis versus other mechanisms.

In addition to being widely prevalent and at times, even being a prognostic comorbidity, CVD can also be triggered and caused by COVID-19 in patients with no prior history of heart disease. In a specific case study of a patient without previous history of cardiovascular disease, elevated J o u r n a l P r e -p r o o f Journal Pre-proof levels of cardiac injury biomarkers high-sensitivity troponin T and NT-proBNP, acute myopericarditis with increased wall thickness and severe left ventricular dysfunction were reported one week after the respiratory symptoms were completely resolved (Inciardi et al., 2020) . Although underlying disease mechanisms are not well understood, these findings suggest significant cardiac involvement in COVID-19.

Direct Mechanisms: In addition to ACE 2 receptor, which serves as the main anchor point for SARS-CoV-2, cellular proteases such as serine protease TMPRSS2 and cathepsins (cathepsin B and cathepsin L) play an important role in viral entry by promoting viral fusion with host cells (Hoffmann et al., 2020) . In humans, ACE 2 receptor expression is highest in the digestive tract, followed by kidney, testis, heart and lungs (Chen, Li, Chen, Feng, & Xiong, 2020) . A detailed cellular level ACE2 expression analysis in heart reported by two independent studies revealed that, amongst various cells in heart, ACE2 was most highly expressed in pericytes, which line the microvasculature, followed by vascular smooth muscle cells, fibroblasts and cardiomyocytes (L. Litviňuková et al., 2020) . In addition, cardiac expression analysis of viral entry promoting proteases TMPRSS2 and cathepsin L, encoded by genes TMPRSS2 and CTSL respectively, revealed that TMPRSS2 was minimally expressed across all cardiac cell types, while CTSL displayed low levels of expression in fibroblasts, macrophages, adipocytes and cardiomyocytes (Tucker et al., 2020) .. Recent articles report the presence of SARS-Cov2 viral particles in cardiac tissue including cardiomyocytes, endothelial cells, mesenchymal cells, and inflammatory cells (Dolhnikoff et al., 2020) Indirect Mechanisms: In addition to the potential direct mechanisms of infection of the myocardium by SARS-CoV-2, cardiac damage can also be triggered by multiple indirect mechanisms in COVID-19 patients. Systemic hyper-inflammation triggered by SARS-CoV-2 infection in the lungs, the 'cytokine storm', may indirectly lead to cardiac damage. Several clinical reports on COVID-19 patients reported significantly elevated inflammatory biomarkers in circulation, including interleukin (IL)-2, IL-6, IL-7, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), tumor necrosis factor-α (TNF-α), interferon-γ inducible protein (IP)-10, C-reactive protein (CRP), ferritin and procalcitonin (Richardson et al., 2020; Ruan, Yang, Wang, Jiang, & Song, 2020) . Although triggered by local infection in the lungs, the increased systemic levels of these inflammatory cytokines activate inflammatory and maladaptive remodeling pathways in multiple organs, including the heart.

Increases in proinflammatory cytokines are involved in the development of cardiac disease. For example, aberrant expression of proinflammatory cytokines TNF-α, IL-1β, IL-6, and MMPs in the heart are also thought to contribute to the onset of myocardial infarction (MI) (Prabhu & Frangogiannis, 2016) . In addition, increases in inflammatory cytokine production has been correlated with aberrant intracellular Ca2+ regulation, a reduction in repolarizing potassium (K+) currents and altered expression of connexin 43 in cardiomyocytes lining the infarct border zone, leading to electrical disturbances in the heart, or cardiac arrhythmias (Pinto & Boyden, 1999) . Indeed, increased expression of CRP is associated with the development of atrial fibrillation J o u r n a l P r e -p r o o f Journal Pre-proof (AF) (Bruins et al., 1997) . With respect to COVID-19, multiple clinical studies now report a significant arrhythmogenic burden in severely infected patients including, heart palpitations and tachycardia have also been reported (Driggin et al., 2020) .

Recent reports also highlight the presence of coagulation abnormalities in COVID-19 patients that led to blood clots and, ultimately to multi-organ failure, including HF. Coagulation is triggered by the activation of cascade of proteins that include coagulation factors, thrombin and fibrinogen. Once formed these blood clots are systematically degraded by specific enzymes such as plasmin, resulting in the formation of fibrin degradation products. D-dimer is one of the main fibrin degradation products and is used as a clinical marker for deep vein thrombosis (DVT), pulmonary embolism (PE) or disseminated intravascular coagulation (DIC). Patients with COVID-19 often have elevated D-dimer levels and high D-dimer levels which correlate with disease severity and increased risk of death (Guan, Ni, et al., 2020; F. Zhou et al., 2020) . While the exact underlying mechanisms are not completely understood, multiple phenomena could contribute to this condition. Recent studies suggest that SARS-Cov2 can directly infect and kill endothelial cells exposing the thrombogenic basement membrane and activating the coagulation cascade. An autopsy study revealed that deep vein thrombosis is present in 7 of 12 patients who died of COVID-19 and in whom venous thromboembolism was not suspected prior to death (Wichmann et al., 2020) . In addition to direct endothelial cell injury, acute immobilization, especially in critically ill patients in ICU, increase in clotting factor VIII, fibrinogen, blood viscosity and presence of neutrophil extracellular traps (NETs) (Maier et al., 2020) can together contribute to hypercoagulable state in COVID-19 patients. Coagulation abnormalities triggered by COVID-19 can also directly and indirectly lead to cardiovascular problems. Micro-emboli caused by damaged endothelium or a hyper-coagulable state could destabilize existing coronary artery plaques precipitating a type I myocardial ischemia (MI) (Libby et al., 2018) . ARDS is the central feature of COVID-19 and the lungs are the most severely affected organ in these patients. Dyspnea has been reported in over 50% of all COVID-19 positive patients and is another common feature in patients with severe disease (Allali et al., 2020) . Pulmonary edema and severe inflammation in lungs lead to reduced gaseous exchanges and result in systemic hypoxemia that affects multiple organs, including heart. This respiratory derangement triggered by COVID-19 could lead to a mismatch between oxygen supply and demand, resulting in type 2 MI (Bandyopadhyay et al., 2020) .

Significant immunological changes have also been reported in patients with severe COVID-19 infection, such as the cytokine storm, a decrease in lymphocyte count (both CD4+ and CD8+ Tcells) below the normal levels, also called as lymphopenia (Qin et al., 2020) (Wilk et al., 2020) and T cell exhaustion (Diao et al., 2020) . Adaptive immunity, specifically through cytotoxic T-cells play an important role in mounting an effective immune response against viral infections, including SARS-Cov2 and is therefore critical for effective recovery. Several studies have reported lymphopenia in a significant proportion of patients with confirmed COVID-19 infection (Ding, Lu, Fan, Xia, & Liu, 2020 ) (G. (Guan, Ni, et al., 2020) (Han et al., 2020) . Lymphopenia is now, a well-established hallmark feature of COVID-19 infection (Bermejo-Martin et al., 2020) .

While the precise underlying mechanisms of lymphopenia are unknown, recent reports demonstrate that SARS-Cov2 can directly infect and replicate in both B and T-lymphocytes triggering apoptosis in these cell types (Pontelli et al., 2020) . In addition to direct infection by SARS-Cov2, multiple other mechanisms such as J o u r n a l P r e -p r o o f Journal Pre-proof cytokine storm (Fathi & Rezaei, 2020) and elevated systemic lactic acid levels could contribute to lymphopenia . In addition to a significant reduction in lymphocyte number, functional analysis of lymphocyte populations reveals that T cells from COVID-19 patients have significantly higher levels of PD-1 (programmed cell death 1) compared to healthy controls suggesting that T-cell exhaustion or anergy could further contribute to the ineffective immune control over viral replication to facilitate disease progression (Diao et al., 2020) .

Previously, lymphocytopenia has been associated with cardiovascular diseases, independent of COVID-19 infection. In a study on 392 patients with Heart Failure with Reduced Ejection Fraction (HFrEF), lymphocytopenia was strongly associated with more severe (NYHA Class III and IV) as compared to milder (NYHA Class I and II) heart disease (Yucel et al., 2015) . (Agnoletti et al., 2004) In fact relative lymphocyte concentration is now recommended as a prognostic marker in patients with acute as well as chronic coronary artery disease (Ommen et al., 1998) (Ommen, Gibbons, Hodge, & Thomson, 1997) . Currently, there is no well-established causative relationship between lymphocytopenia and cardiovascular disease. However, animal studies suggest that interferon-γ secreted by T lymphocytes modulates smooth muscle proliferation during vascular repair. In addition, studies in rats which lack T-lymphocytes show larger arterial lesions after vascular injury, as compared to controls (Hansson et al., 1991) . Together, these data all suggest that lymphocytopenia triggered by SARS-Cov2 infection can potentially add to the cardiovascular burden in COVID-19 patients.

COVID-19-associated systemic hyper-inflammation, cardiac arrhythmia, hemodynamic and respiratory derangement can induce cardiac stress. Sometimes, the stress can be severe enough to result in significant myocardial injury, which causes substantial cardiomyocyte death in the short term and potentially lead to onset of HF in the long run.

HF is a condition in which the heart can't pump enough blood to meet the body's needs due to aberrant cardiac structure and function, and affects nearly 6 million people in the US alone (Writing Group et al., 2016) . Significant research has been carried out to understand the molecular mechanisms that promote ischemic, non-ischemic and bacterial/viral triggered HF (Fung, Luo, Qiu, Yang, & McManus, 2016; Sikder et al., 2018) . Chronic inflammation is an important pathogenic driver of HF, leading to cardiac fibrosis, an abnormal thickening and scarring of cardiac tissue, and eventually to cardiac dysfunction and patient death (Seta, Shan, Bozkurt, Oral, & Mann, 1996) . Different types of immune cells play an important role in promoting and regulating cardiac inflammation, and timing as well as identity of inflammatory cell infiltration in heart may vary, depending on the stimulus Inflammation Mechanisms Underlying Ischemic Cardiac Injury:

Cardiac ischemia caused by formation of an occlusive thrombus within the coronary artery leads to myocyte necrosis, triggering intense sterile inflammation and immune cell infiltration in hearts. In the case of an ischemic injury, neutrophils are the first immune cells to infiltrate cardiac tissue (between 12 hours to 3 days post injury) (Dewald et al., 2004; Frangogiannis, 2012) . In addition to secreting matrix metalloproteases to help clear the dead cells and debris, neutrophils also produce IL-6, which plays a pivotal role in the recruitment of monocytes/macrophages to the J o u r n a l P r e -p r o o f Journal Pre-proof heart. Two distinct phases of monocyte recruitment have been identified in healing myocardial infarcts. After ischemic injury in mice, the first phase of monocyte/macrophage infiltration comprises of C-C chemokine receptor 2 (CCR2)+ monocytes which express high levels of lymphocyte antigen 6 complex (Ly6c hi ) on their membranes. These cells reach their peak infiltration by 3 days post MI and predominantly promote acute inflammation and further removal of dead cells. In the second phase, CCR2+ monocytes which express lower levels of Ly6C (Ly6C low ) reach peak infiltration by day 7 and are more reparative in nature; they promote the activation and transformation of fibroblasts to collagen producing myofibroblasts to generate scar tissue, a crucial step needed for wound healing (Nahrendorf et al., 2007) . In humans, classical monocytes are identified by membrane proteins that are Cluster of Differentiation (CD)14 ++ CD16which are functionally similar to murine Ly6C high monocytes, whereas nonclassical monocytes are CD14 + CD16 ++ and more closely resemble murine Ly6C low cells. In addition to the innate immune cell infiltration, adaptive immune cells, predominantly Tlymphocytes also infiltrate the injured myocardium. Specifically, CD3+ CD4+ helper, CD8+ cytotoxic, and Foxp3+ regulatory T-cell numbers in heart are significantly increased (up to 10 fold) by day 7 after coronary ligation in mice. During the early stages of MI, CD4+ T-cells are shown to promote wound healing and tissue repair (Hofmann et al., 2012) . However, in chronic ischemic HF, CD4+ T-cells impart pro-inflammatory and detrimental effects on the heart that promote adverse remodeling, and antibody mediated CD4+ T-cell ablation alleviated pathological LV remodeling, suggesting pathological role for T-cells during these later stages of MI (Bansal et al., 2017) . Replacement of dead cardiac tissue with fibrotic myocardial scar is absolutely crucial for maintaining the structural integrity of the cardiac wall; inhibiting scar formation can lead to ventricular dilation or even ventricular rupture (van den Borne et al., 2010) . However, conversely, persistent activation and propagation of myofibroblasts can lead to pathological fibrosis, decreasing cardiac function, stiffening the heart, and eventually causing HF and death (Jugdutt, 2003; Turner & Porter, 2013) . Although the precise molecular mechanisms underlying onset of pathological fibrosis remain unclear, transforming growth factor-beta (TGF-β) is thought to play a central role in fibroblast proliferation and fibroblast-tomyofibroblast conversion. Inhibiting TGF-β inhibits pathological fibrotic remodeling in mice, suggesting it may be a viable therapeutic target, although this has yet to be determined in humans (Okada et al., 2005) .

Hypertension is a common risk factor for non-ischemic cardiac injury and HF (Lawes, Vander Hoorn, Rodgers, & International Society of, 2008) Hypertensive heart disease is associated with cardiac hypertrophy, cardiac fibrosis and manifests clinically as systolic or diastolic HF (Kenchaiah & Pfeffer, 2004; Levy, Larson, Vasan, Kannel, & Ho, 1996; Messerli, Rimoldi, & Bangalore, 2017; Vasan et al., 2001) . Transaortic Constriction (TAC), a surgical procedure that involves placing an elastic band around the aorta to induce cardiac pressure overload is a wellestablished model of nonischemic HF in mice (Rockman et al., 1991) . TAC induces low-grade cardiac inflammation, adverse cardiac remodeling, and progressive cardiac dysfunction. In addition, Angiotensin II (ATII) infusion is another well-established experimental model for pressure overload mediated non-ischemic injury to heart (Harada et al., 1998) . The contribution of inflammation to pressure overload induced HF is a well-studied phenomenon, with multiple J o u r n a l P r e -p r o o f immune cell types infiltrating the heart. In contrast to ischemic injury, non-ischemic injury causes minimal necrotic death of cardiomyocytes and negligible cardiac neutrophil infiltration to the heart. Recent studies have shown that F4/80+ CCR2+ monocytes are one of the first immune cell types to infiltrate the heart in significant numbers after TAC. The infiltration of these monocytes is mediated by a specific chemokine, monocyte chemoattractant protein -1 (MCP-1) and they reach peak infiltration by 7 days post TAC (Xia et al., 2009) . Unlike ischemic cardiac injury, CCR2+ Ly6C low macrophage population significantly increases, in response to TAC, making up over 80% of all the macrophage population in heart, 6 days post TAC (Weisheit et al., 2014) . Blocking TAC induced cardiac infiltration of CCR2+ macrophages either pharmacologically, using a CCR2 antagonist (RS-504393) or with an antibody mediated CCR2+ monocyte depletion strategy, alleviates maladaptive cardiac remodeling and protects the heart from pressure overload induced failure (Patel et al., 2018) . The adaptive immune system also plays an important role in regulating the cardiac microenvironment after TAC. Although temporal studies on adaptive immune cell infiltration in heart after non-ischemic stress have not been carried out extensively, multiple studies have highlighted the role of T-cells in reparative and maladaptive cardiac remodeling following pressure overload. Interestingly, while no significant T-cell infiltration in the left ventricle (LV) was observed, 48 hours post TAC, infiltration of T cells became prevalent after 2 weeks, peaking at 4 weeks after TAC. Using a T-cell deficient mouse model (T-cell receptor knock out TCRα -/-), T-cell recruitment into the LV correlated with adverse remodeling; mice lacking T-cell receptor showed resistance to pressure overload induced maladaptive cardiac remodeling and had preserved cardiac function (Nevers et al., 2015) . Similar results were observed when T-cells were deleted in normal mice using anti CD3 antibody suggesting that T-cell recruitment into the LV is a contributing factor to pathological cardiac remodeling in HF. Similar observations were reported in patients with NYHA class III and class IV non-ischemic HF, where CD3+ T cells infiltrated the LV of patients with nonischemic end stage HF, and this was associated with significant cardiac hypertrophy and fibrosis. Moreover, by blocking T cell co-stimulation with antigen presenting cells such as Dendritic cells (DCs), B -lymphocytes and macrophages using a monoclonal antibody that blocks T-cell activation (Abatacept). Abatacept administered mice had significantly preserved cardiac function and reduced fibrotic response after TAC, highlighting the importance of the adaptive immune system in pathological cardiac remodeling (Kallikourdis et al., 2017) Inflammation Mechanisms Underlying Virus mediated Cardiac Injury: Viral infections are one of the common causes of myocarditis (Kindermann et al., 2012) . Several viruses including adenovirus, herpesviruses, and influenza can cause myocarditis in humans (Klingel et al., 2004) . However, Coxsackievirus type B (CVB) has have high tropism for cardiomyocytes, endothelial cells, and leukocytes in humans and CVB mediated myocarditis has been well studied (P. K. Cheung et al., 2005) . CVB particles can directly induce myocardial injury, even in mice lacking B and T-cells, as demonstrated by CVB induced myocarditis in mice with severe combined immune deficiency (Chow, Beisel, & McManus, 1992) . In addition, CVB viral particles also activate both innate and adaptive immune systems and cause cardiac injury through inflammatory mechanisms. CVB infection of endothelial cells upregulates the expression of lymphocyte function associated antigen 1 (LFA-1), which promotes leukocyte extravasation and inflammation in heart (Shim, Kim, Cho, & Nam, 2014) . Significant J o u r n a l P r e -p r o o f upregulation of F4/80+ macrophages has been observed in mice infected with CVB3 on post infection day 12 (Fairweather et al., 2006) and cardiac infiltration of CD3+ T-cells has been reported by post infection day 7 (Shim et al., 2014) . Depletion of T lymphocytes decreases mortality rate and reduces cardiac inflammation and injury after CVB3 infection (Woodruff & Woodruff, 1974) highlighting the pathological role of T-cells in viral myocarditis. However, recent reports show that CD4+CD25+FoxP3+ Treg cells exert protective effects through TGF-β which is known to suppress inflammation (Y. Shi et al., 2010) . Together, these data highlight the significant and complex interplay of immune cells in regulating cardiac function.

Although no direct experimental evidence exists for understanding the molecular mechanisms that regulate COVID-19 induced remodeling in heart as yet, there seems to be some commonality between the immunological mechanisms underlying COVID-19 induced myocardial injury and ischemic/non-ischemic HF and viral myocarditis. As reported in ischemic and to a lesser extent in non-ischemic HF, myocardial infiltration of neutrophils has also been reported in hearts of COVID-19 patients, however, their subtype identity is currently unknown. (Yao et al., 2020) . Recent data suggest that the network of extracellular fibers secreted by neutrophils, also termed neutrophil extracellular traps (NETs), aggravate myocardial ischemia/reperfusion injury in CVD patients. However, breakdown of NETs with DNase I reduces neutrophil influx into the infarcted heart and improves cardiac function (Savchenko et al., 2014) . Interestingly, a recent report demonstrated a higher level of biomarkers for NETs in COVID-19 patients that were on mechanical ventilation, as compared to hospitalized patients breathing room air (Zuo et al., 2020) . Together, these preliminary data suggest that significant increases in neutrophil count can exacerbate disease severity in COVID-19 patients and may also promote myocardial damage.

Multiple autopsy studies report an infiltration of macrophages and CD4+ T lymphocytes in the myocardium of COVID-19 patients (Yao et al., 2020) . Myocyte damage and lymphocytic myocarditis have also been independently confirmed by recent autopsies carried out on multiple COVID-19 patients from Seattle and Germany (Bradley et al., 2020; Wichmann et al., 2020) Recently, SARS-CoV-2 viral particles have been identified in cardiac macrophages, suggesting that these cells can be directly infected by the virus, potentially transmitting the disease systemically to multiple tissues (Tavazzi et al., 2020) . While the exact molecular identity of these macrophages is currently unknown, the correlation of macrophage infiltration with cardiomyocyte necrosis and the systemic hyperinflammatory conditions in patients suggest that these macrophages could be pro-inflammatory in nature. The infiltration of neutrophils, macrophages and CD4+ T lymphocytes in COVID-19 patients can promote the activation of fibroblasts to myofibroblasts in heart, which could lead to pathological cardiac remodeling and fibrosis in the long term, leading to development of HF and potentiating earlier death in infected (or even recovered) patients. Recently, 78% of 100 recovering patients evaluated 71 days after confirmed COVID-19 diagnosis showed cardiovascular involvement as detected by magnetic resonance imaging, irrespective of preexisting conditions and severity of COVID-19 disease. 76% of patients had detectable high-sensitivity troponin, a cardiac injury biomarker and 60% had myocardial inflammation, edema and/or diffuse myocardial fibrosis as determined by abnormal native T1 and T2 measures. Compared with both healthy and risk factor-matched controls, patients who recently recovered from COVID-19 had lower left ventricular and right J o u r n a l P r e -p r o o f ventricular ejection fractions, higher left ventricle volumes and masses (Puntmann et al., 2020) These findings highlight COVID-19 related cardiovascular burden in patients, even after recovery, and the possibility of residual left ventricular dysfunction and ongoing inflammation post-infection, which may lead to new-onset heart disease and other cardiovascular complications in the near future.

COVID-19 has already infected over 27 million people worldwide and has resulted in over 880,000 (figures are current at the time of writing these manuscript) deaths across the globe. This pandemic is nowhere near over or under control yet and continues to actively spread across the U.S. and rest of the world. Though tremendous efforts and resources have been dedicated towards developing a vaccine or a cure, there is yet no effective way to treat this disease. CVD remains the most significant comorbidity associated with increased mortality in COVID-19 infection. While the underlying disease mechanisms are not completely understood, preliminary data suggest that both local and systemic inflammation play a critical role in evoking and potentiating existing or new cardiac functional abnormalities. While myocardial infiltration of immune cells and cardiomyocyte necrosis are short term complications of COVID-19, the longterm effects remain to be seen. These could easily include cardiac hypertrophy, cardiac fibrosis and decreased cardiac output, leading to potentiated cardiac dysfunction. Therefore, patients who recover from severe COVID-19 could be at increased risk of developing HF, and there is a reason and need to continue monitoring these patients for cardiac health issues in the long run. Given the worldwide prevalence of this disease and the strong association with CVDs, additional studies are needed to gain a better understanding of the molecular mechanisms that drive COVID-19 related cardiac remodeling and to develop effective screening and therapeutic interventions against COVID-19-associated HF in the future. : Common mechanisms between ischemic injury induced and COVID-19 induced cardiac remodeling. A) Myocardial ischemia induces significant cardiomyocyte death followed by recruitment of innate (neutrophils, monocytes, macrophages) and adaptive immune cells (Tlymphocytes) which promote dead cell clearance and wound healing in the short term. In the long run, this immune cell infiltration and associated cytokine release transform fibroblasts to myofibroblasts, resulting in excessive fibrosis and maladaptive cardiac remodeling which may lead to HF. B) Preliminary autopsy reports of COVID-19 patients confirmed infiltration of both innate (monocytes and macrophages) and adaptive immune cells (lymphocytes) in myocardium. In the long run, this immune cell infiltration can potentially trigger maladaptive cardiac remodeling resulting in cardiac fibrosis and decreased cardiac function in patients who recover from severe COVID-19 disease This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; https://smart.servier.com. Following the production of structural proteins, nucleocapsids are assembled in the cytoplasm and followed by budding into the lumen of the endoplasmic reticulum (ER)-Golgi intermediate compartment. Virions are then released from the infected cell through exocytosis. The insert highlights S1 and S2 domains of virus spike protein and the polybasic RRAR cleavage site that enhances its association with NPR-1 receptor. (figure created with biorender.com) FUNDING This work was supported by Masonic Medical Research Institute internal funding support to MIK, JM and SU. MIK is also supported by R01HLHL122238, 2R01HL102368-06A1 and 1 R01 CA190838-01A1. JM is also supported by R01HLHL122238, 2R01HL102368-06A1

Immune activation in severe heart failure: Does etiology play a role?

Dyspnea: The vanished warning symptom of COVID-19 pneumonia

COVID-19

COVID-19 Pandemic: Cardiovascular Complications and Future Implications

Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure

Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection

COVID-19 and cardiac arrhythmias

SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. bioRxiv

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Histopathology and Ultrastructural Findings of Fatal COVID-19 Infections. medRxiv

Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a into the central nervous system. bioRxiv

Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

Clinical and immunological features of severe and moderate coronavirus disease 2019

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Specific interactions of mouse organ proteins with the 5'untranslated region of coxsackievirus B3: potential determinants of viral tissue tropism

Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury

Neuropilin-1 is a host factor for SARS-CoV-2 infection. bioRxiv

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan

SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Role of innate and adaptive immune mechanisms in cardiac injury and repair

Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart

Lymphopenia in COVID-19: Therapeutic opportunities

Unexpected Features of Cardiac Pathology in COVID-19 Infection

The Variety of Cardiovascular Presentations of COVID-19

Coronavirus spike proteins in viral entry and pathogenesis

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Clinical Characteristics of Coronavirus Disease 2019 in China

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease

Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia

T lymphocytes inhibit the vascular response to injury

Acute pressure overload could induce hypertrophic responses in the heart of angiotensin II type 1a knockout mice

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice

First Case of 2019 Novel Coronavirus in the United States

Coronavirus Spike Protein and Tropism Changes

Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Immune Parameters and COVID-19 Infection -Associations With

Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

T cell costimulation blockade blunts pressure overload-induced heart failure

Cardiac remodeling in systemic hypertension

Update on myocarditis

Host cell proteases controlling virus pathogenicity

Molecular pathology of inflammatory cardiomyopathy

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Chilblain-like lesions on feet and hands during the COVID-19 Pandemic

Global burden of blood-pressure-related disease

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

The progression from hypertension to congestive heart failure

Acute respiratory failure in COVID-19: is it "typical

Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Cells and gene expression programs in the adult human heart. bioRxiv

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

The Transition From Hypertension to Heart Failure: Contemporary Update

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions

Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure

Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure

Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease

Predictive power of the relative lymphocyte concentration in patients with advanced heart failure

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

CCR2(+) Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload

COVID-19, SARS and MERS: are they closely related?

Electrical remodeling in ischemia and infarction

Infection of human lymphomononuclear cells by SARS-CoV-2. bioRxiv

The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently

Recovered From Coronavirus Disease 2019 (COVID-19)

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice

Basic mechanisms in heart failure: the cytokine hypothesis

Structural basis of receptor recognition by SARS-CoV-2

Human iPSC-Derived Cardiomyocytes are Susceptible to SARS-CoV-2 Infection. bioRxiv

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway

Coxsackievirus B3 regulates T-cell infiltration into the heart by lymphocyte function-associated antigen-1 activation via the cAMP/Rap1 axis

Group G Streptococcus Induces an Autoimmune Carditis Mediated by Interleukin 17A and Interferon gamma in the Lewis Rat Model of Rheumatic Heart Disease

Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research

Role of hemagglutinin cleavage for the pathogenicity of influenza virus

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Furin at the cutting edge: from protein traffic to embryogenesis and disease

Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 mediated myocarditis. medRxiv

Function and fate of myofibroblasts after myocardial infarction

Myocardial remodeling after infarction: the role of myofibroblasts

Endothelial cell infection and endotheliitis in COVID-19

Impact of high-normal blood pressure on the risk of cardiovascular disease

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Ly6C(low) and not Ly6C(high) macrophages accumulate first in the heart in a model of murine pressure-overload

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

A single-cell atlas of the peripheral immune response to severe COVID-19. medRxiv

Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease

Heart Disease and Stroke Statistics-2016 Update: A Report From the

The SARS-CoV-2 outbreak: What we know

Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

FURIN Expression in Vascular Endothelial Cells Is Modulated by a Coronary Artery Disease-Associated Genetic Variant and Influences Monocyte Transendothelial Migration

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Zoonotic origins of human coronaviruses

Lymphocytopenia is associated with poor NYHA functional class in chronic heart failure patients with reduced ejection fraction

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Systemic analysis of tissue cells potentially vulnerable to SARS-CoV-2 infection by the proteinproofed single-cell RNA profiling of ACE2, TMPRSS2 and Furin proteases. bioRxiv

A Novel Coronavirus from Patients with Pneumonia in China

Neutrophil extracellular traps in COVID-19